Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASCO 2020 | Update on IMGN632: CD123 antibody-drug conjugate for R/R AML and BPDCN

Naval Daver • 29 May 2020

ASCO 2020

Acute Myeloid Leukemia Leukemia Antibodies Azacitidine IMGN632 Venetoclax

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase I/II study (NCT03386513) of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and other CD123-positive malignancies. Additionally, Dr Daver outlines the Phase Ib/II study of IMGN632 study (NCT04086264) as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive AML. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

New treatments in AML: FLT3 inhibitors & novel combinations

Gail Roboz et al. • 4 Sep 2023

Investigating the combination of pivekimab sunirine, azacitidine & venetoclax in R/R AML

Naval Daver • 12 Dec 2022

The importance of CD47 as a target in MDS and AML

Naval Daver • 12 Dec 2022

Investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with AML

Naval Daver • 12 Dec 2022

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024